All In Biotech

Drug Trial Radar · NCT00455533

Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer

A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women With Early Stage Breast Cancer

Last checked: Nov 20, 2026Latest source record: Feb 24, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 384 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

384

Actual

Start

Oct 2007

Primary completion

Dec 2009

Study completion Dec 2009

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Apr 3, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate the effectiveness of ixabepilone when given after doxorubicin plus cyclophosphamide (AC) compared to standard treatment of paclitaxel given after doxorubicin plus cyclophosphamide in patients with early stage breast cancer. In addition the study will verify predefined biomarkers as well as discover new biomarkers that could identify patients who are more likely to respond to ixabepilone than standard paclitaxel based therapy.

Conditions

  • Breast Cancer

Interventions

  • IxabepiloneDrug

    Intravenous Solution, intravenous (IV), 40mg/m², Day 1 every 21 days, 12 Weeks

  • PaclitaxelDrug

    Intravenous Solution, IV, 80mg/m², Weekly, 12 Weeks

  • CyclophosphamideDrug

    Intravenous Solution, IV, 600mg/m², Day 1 every 21 days, 12 Weeks

  • DoxorubicinDrug

    Intravenous Solution, IV, 60mg/m², Day 1 every 21 days, 12 Weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Pathologic Complete Response (pCR)Time frame: at surgery (performed 4-6 weeks after the last dose of 12 weeks of therapy)
  2. Percentage of Participants Achieving Pathologic Complete Response (pCR) in Biomarker-Defined PopulationsTime frame: pCR evaluated at time of surgery (4-6 weeks after the last dose of therapy); mandatory tumor tissue biopsy obtained prior to treatment.
  3. Percentage of Participants Achieving Pathologic Complete Response (pCR) in 20- and 26-Gene Model SubgroupsTime frame: pCR evaluated at time of surgery (4-6 weeks after the last dose of therapy); mandatory tumor tissue biopsy obtained prior to treatment.

Locations

49 sites in 15 countries. Site status is shown where the registry gives one.

  • Comprehensive Cancer Center

    Palm Springs, California

  • Northwest Oncology & Hematology Associates

    Coral Spring, Florida

  • Florida Cancer Research Institute

    Davie, Florida

  • Medical Specialists Of Palm Beaches

    Lake Worth, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • University Medical Center, Inc

    Louisville, Kentucky

  • University Of New Mexico Cancer Center

    Albuquerque, New Mexico

  • Albert Einstein Cancer Center

    The Bronx, New York

  • Virginia Mason Medical Center

    Seattle, Washington

  • Providence Cancer Center

    Spokane, Washington

  • Local Institution

    Buenos Aires, Buenos Aires, Argentina

  • Local Institution

    Buenos Aires, Buenos Aires, Argentina

  • Local Institution

    Capital Federal, Buenos Aires, Argentina

  • Local Institution

    Capital Federal, Buenos Aires, Argentina

  • Local Institution

    Salzburg, Austria

  • Local Institution

    Vienna, Austria

  • Local Institution

    Bordeaux, France

  • Local Institution

    Saint-Herblain, France

  • Local Institution

    Düsseldorf, Germany

  • Local Institution

    Erlangen, Germany

  • Local Institution

    Jena, Germany

  • Local Institution

    Bhopal, India

  • Local Institution

    Hyderabad, India

  • Local Institution

    Mumbai, India

  • Local Institution

    Vellore, India

  • Local Institution

    Bangalore, Karnataka, India

  • Local Institution

    Trivandrum, Kerala, India

  • Local Institution

    Pune, Maharashtra, India

  • Local Institution

    New Delhi, National Capital Territory of Delhi, India

  • Local Institution

    Bologna, Italy

  • Local Institution

    Lima, Lima Province, Peru

  • Local Institution

    Lima, Lima Province, Peru

  • Local Institution

    Callao, Provincia Constitucional del Callao, Peru

  • Local Institution

    Cebu City, Philippines

  • Local Institution

    Davao City, Philippines

  • Local Institution

    Quezon City, Philippines

  • Local Institution

    Kazan', Russia

  • Local Institution

    Moscow, Russia

  • Local Institution

    Saint Petersburg, Russia

  • Local Institution

    Singapore, Singapore

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.